We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Response of Hepatic Tumors to Radioembolization (RESRAD)

This study has been withdrawn prior to enrollment.
(Lack of enrollment)
ClinicalTrials.gov Identifier:
First Posted: January 24, 2013
Last Update Posted: June 9, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Zurich

The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis. Patients are not a candidates for liver transplantation and have only limited extrahepatic disease. All patients are treated with radioembolization. Primary endpoint is the percentage of patients that can be downstaged to resectability.

Secondary endpoints are radiologic response to radioembolization,tissue response to radiomembolization and systemic immune response and intra-tumoral T-cell response to radioembolization.

  • Trial with radiotherapy

Condition Intervention Phase
Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma Liver Metastasis Radiation: Injection of Ytttrium-90 microspheres into the hepatic artery Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiologic, Histologic and Immunologic Response to Radioembolization of Hepatic Tumors

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Primary endpoint ist the percentage of patients that can be downstaged to resectability [ Time Frame: 2012 to 2015 ]

Secondary Outcome Measures:
  • Histologic response to radioembolization [ Time Frame: 2012 to 2015 ]
    Resected specimen will be examined for changes related to radioembolization like endothelial damage, necrosis, fibrosis

  • Immunological response to radioembolization [ Time Frame: 2012 to 2015 ]

    Circulating T-cells and tissue based T-cells will be examined for their response to tumor antigens, clonal proliferation.

    Serologic response to tumor antigens will be examined

Enrollment: 0
Study Start Date: October 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radioembolization
Radioembolization using Yttrium-90 microspheres using a transarterial approach
Radiation: Injection of Ytttrium-90 microspheres into the hepatic artery
INjection of Y-90 particles into the hepatic artery using endovascular access


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria: - Patients already considered for radioembolization fulfil criteria to be included in the study. If radioembolization is not considered by the tumor board, inclusion in the study should not be considered.

- Non-resectable or borderline resectable liver tumors (HCC, CRCM or CCC) as as-sessed by a multidisciplinary tumor-board. Non-resectability or borderline resectablily is based closeness to essential nonresectable structures (f.e. the portal vein bifurca- tion or hepatic vein trifurcation) or insufficient liver volume after resection, general performance status of the patient.

Chemotherapy (mostly applicable to CRCM) should be termininated at least 4 weeks prior to enrolling patients in the study.

  • Concomitant manoevers to manipulate liver volume like portal vein embolization or ligation and two-stage resections are allowed
  • Male or female patients 18-99 years of age
  • Presentation of the case at the Multidisciplinary Meeting attended by hepatobiliary surgeons, oncologists, hepatologists and radiologists
  • Written informed consent given by the patient
  • Adequate liver function or kidney function tests, including any of the following. It is possible to perform endoscopic or percutaneous stent placement to achieve normal-isation of laboratory parameters.
  • Women who are not breastfeeding and are using effective contraception if sexually active, who are not pregnant and agree not to become pregnant during the 12 months thereaf-ter. A negative pregnancy test before inclusion into the trial is required for women < 50 years. Men who agree not to father a child during participation in the trial or during the 12 months thereafter.
  • Effective contraception

Patient compliance and geographic proximity

Exclusion criteria: -Patients with no clinical indications for radioembolization (resectable tumors, no need for downsizing)

  • contraindications on ethical grounds,
  • women who are pregnant or breast feeding,
  • significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardi-ovascular disease, etc) as based on above mentioned labaratory values or preopera-tive cardiac assessment making the patient unsuitable for major surgery known or suspected non-compliance, drug or alcohol abuse, enrolment into a clinical trial within last 4 weeks, extrahepatic tumor burden, as evaluated by PET/CT or chest CT. Potentially resectable small lung nodules or hilar lymphadenopathy by CT or PET in case of MCRC mandate systemic chemotherapy prior to enrolment into this trial if not already performed. The patient may be en-rolled into this trial to be downstaged by radioembolization after finishing systemic chemotherapy.
  • Anatomic variant in arteriogram which prevents selective delivery of the chemother-apy to the liver (discussed within group of principal investigators)
  • Life expectancy < 3 months
  • Candidacy for liver transplantation in the case of HCC
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01775280

University Hospital Zurich, Divisions of Visceral Surgery and Nucelar Medicine
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Principal Investigator: Erik Schadde, MD University Hospital Zurich, Division of Visceral and Transplant Surgery
Principal Investigator: Niklaus Schaefer, MD University Hospital Zurich, Division of Nuclear Medicine
  More Information

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01775280     History of Changes
Other Study ID Numbers: USZ-ZH-VIS-RESRAD
First Submitted: January 22, 2013
First Posted: January 24, 2013
Last Update Posted: June 9, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases